As per the terms of the deal, CDRD Ventures will drive the development of projects together with Roche.
The agreement allows CVI to support Canadian health researchers for developing novel therapeutics targeting the diseases with high unmet medical need.
CDRD president and CEO Natalie Dakers said this will allow them to address the commercialization gap between academia and the private sector, and in doing so, bring new therapeutics to the patients who need them.